Fazax is pleased to announce a strategic update regarding its dermatology pipeline. The research and optimization cycle for Zerpix® (topical gel) has successfully concluded, moving the biotechnological asset into the final stage of pre-market logistical and regulatory preparation.Developed over several years by the international research centers of Fazax using advanced deep learning neural network models, Zerpix® represents the world’s first metabiotic platform engineered to safely down-regulate cellular senescence. Robust validation frameworks, combining in vivo evaluations and Digital Twin computational modeling, verify a significant rejuvenating effect within the initial 6 to 24 months, with long-term data demonstrating a record-breaking 52% annual reduction in the rate of skin aging. The formulation architecture is based on cell-signaling metabolites from a novel recombinant bacterial strain, exclusively functioning as the unique producer of the highly bioactive h-IMS and SIT-31 molecules.Moving according to our strategic schedule, the official international market availability and commercial launch of the Zerpix® formulation are scheduled to take effect in Summer 2026.